Full text is available at the source.
Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity
Protein-designed lipid nanoparticles for mRNA delivery with low immune response
AI simplified
Abstract
pDLS-LNPs loaded with SARS-CoV-2 spike mRNA achieve superior mRNA delivery compared to the clinically approved BNT162b2 formulation.
- Hydrophilic, nonionic, and biodegradable poly(D, L-serine) lipids may serve as effective alternatives to polyethylene glycol lipids in lipid nanoparticle formulations.
- Systematic structural screening identifies optimal architectures that result in colloidally stable pDLS-LNPs with high mRNA encapsulation and transfection efficiency.
- pDLS-LNPs elicit robust cellular and humoral immune responses in mice without causing systemic toxicity.
- Unlike PEG-based nanoparticles, repeated dosing with pDLS-LNPs triggers minimal anti-pDLS IgM production.
- pDLS-LNPs maintain stability under frozen storage for over 6 months.
AI simplified